Also in this playlist...
This transcript is automatically generated
I got more on -- second more this gee whiz stuff.
Because last week we brought you the man who 3-D printed a human via and we asked -- what's next a no -- a foot well all right.
Those they -- we've got a man with us now whose company printed liver tissue.
He's with us today is name is Keith -- He's chairman and CEO of -- no vote and he is with his right -- -- the program this is very much -- -- -- thing isn't it.
It is thank you very here this morning starts to welcome so I wanna ask you you've you've you've come print out human live -- -- On about -- That's correct we use a 3-D -- printer to lay down cells layer by layer and build them up into a living tissue.
So cute boy you've got right now on -- -- -- you've got you've got the tissue.
If you can string -- -- together are you in a position some years down the road to create a human level.
Well we've got to walk before we can run but what we're doing is building a platform and you have to think about from a business perspective.
The milestones that you can -- so we're about finding the shortest term wins for investors.
What we can use this live report today is talk studies to find better drugs or find drug efficacy and safety.
-- to improve drug outcomes and then longer term we can use the platform.
In academic research labs for example to build towards making larger issues and pull levers okay song kind of off base about how -- how many years before -- printing out -- that's that's way out that.
What you're using this move it to issue for is experiments to see what's toxic to limit to issue that kind of things right.
Yeah and delivers one example of a number two issues that we make we make lung tissue.
We make bone actually in the lab and a number of other tissues and we use that not only for -- studies but for drug discovery.
And there's an opportunity here because about 40% of drug costs actually go to drugs that never make it so you'll hear about a drug it fails in phase three -- testing.
-- to hunt for seeing liver toxicity.
That's because we don't really have the best methods today to see how a drug will be -- the human liver so by making a small piece of liver tissue outside the body.
You can be more predictive of how the drugs actually gonna behave when it gets -- clinical trials -- you are now making a small piece of liver tissue.
What do you make it wrong.
Ball goes into the formal vote in the hand Texas in the -- the tissue what is it.
I think it's a great question so our platform the bio printer can actually take any cells as its source so we can start with a research cell -- that researchers -- worked with for -- long time.
For making a piece of liver tissue that's going to be useful we often start with human cells so there -- -- of Eric and -- and you get them.
From donor tissue men and you can make them up into a small a large number of small liberty issues in a platform that's useful in research.
That's Kevin Murphy you're the CEO of or -- no vote that is a publicly traded company heavily.
That's practice were traded OTC QX.
OT CQ it's OK Kevin -- on Keith I'm SARS I didn't I just -- right.
Keith Murphy thank you very much for joining us thank you very much come again I want if you got -- real progress.
-- -- Thank you and.
Filter by section